Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 8, 2017
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced it will report financial results for the third quarter 2017 as well as provide a corporate update at 4:30 p.m. EST on November 8, 2017.
The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 4495749. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEX™ is a sustained-exposure formulation of the steroid dexamethasone. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial. A set of programs targeting sensorineural hearing loss including age-related hearing loss are in preclinical development. Otonomy’s proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician. For additional information please visit www.otonomy.com.
Heidi Chokeir, Ph.D.
Senior Vice President
Robert H. Uhl
Source: Otonomy, Inc.